Drugs may be considered for ages 10 to 19 only after supervised programs fail. WHO says GLP-1 evidence in children is still too thin.
Recap by typeshit. Full story at USA TODAY.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
A surgeon on social media says the FDA has received two death reports involving black-market retatrutide. No official FDA statement is linked.
Crypto payments to Chinese vendors selling both peptides and fentanyl ingredients rose 32% to $37.3M in 2025, TRM says, with US buyers the largest identifiable source.
A look at how regulators are handling the surge in peptide use, from approved medicines like insulin and GLP-1 drugs to the wider market.
Loading…